한글목차

세계의 프로게스테론 시장은 2024년에 2억 392만 달러로 평가되었고, 2030년에는 2억 4,258만 달러에 이를 전망이며, 예측 기간 동안 CAGR 1.89%로 성장할 것으로 예측됩니다.

황체 호르몬은 호르몬 대체 요법(HRT), 피임약, 불임 치료, 수의학 용도로 널리 사용되는 중요한 호르몬입니다. 배란을 조절하고 임신을 유지하는 데 중요한 역할을 하기 때문에 인간과 동물 모두의 건강 분야에서 필수적인 역할을 하고 있습니다. 불임률 증가와 체외수정(IVF)과 같은 생식 보조 의학(ART)에 대한 접근의 확대는 프로게스테론 기반 제제 수요를 촉진하고 있습니다. 또한 생식과 갱년기 건강에 대한 세계의 의식이 높아지면서 특히 신흥국에서 시장의 성장을 뒷받침하고 있습니다. 그러나 규제의 복잡성, 장기적인 호르몬 요법으로 인한 잠재적 부작용, 원료 공급 및 제조 비용의 변화와 같은 과제에 시장은 계속 직면하고 있습니다.

시장 성장 촉진요인

제약 산업의 성장

주요 시장 과제

안전에 대한 우려 및 부작용

주요 시장 동향

갱년기 장애에 대한 의식 증가

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 프로게스테론 시장에 미치는 영향

제5장 세계의 프로게스테론 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율 및 예측
  • 판매 채널별(직접, 간접)
  • 용도별(호르몬 보충요법, 불임치료, 월경장애, 월경전 증후군(PMS), 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 프로게스테론 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 프로게스테론 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 프로게스테론 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 프로게스테론 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카 프로게스테론 시장 전망

• 시장 규모 및 예측
• 시장 점유율 및 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향 및 발전

• 합병 및 인수
• 제품 출시
• 최근 동향

제13장 세계의 프로게스테론 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계 내 경쟁
• 신규 진입의 가능성
• 공급자의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• NAARI PHARMA Pvt. Ltd
• La Chandra Pharmalab
• BGP Laboratories Private Limited
• VM Lifescience
• Mankind Pharma Ltd
• Bhugan Lifescience Pvt Ltd
• Abcures Biosciences LLP
• Symbiotec Pharmalab
• Granth Pharma Pvt Ltd
• Emote Lifesciences LLP

제16장 전략적 제안

제17장 기업 소개 및 면책사항

영문목차

The Global Progesterone Market was valued at USD 203.92 million in 2024 and is projected to reach USD 242.58 million by 2030, growing at a CAGR of 1.89% during the forecast period. Progesterone is a vital hormone widely used across hormone replacement therapies (HRT), contraceptives, fertility treatments, and veterinary applications. Its critical role in regulating ovulation and sustaining pregnancy makes it essential in both human and animal health sectors. Increasing infertility rates and expanding access to assisted reproductive technologies (ART), such as IVF, are fueling demand for progesterone-based formulations. Rising global awareness of reproductive and menopausal health is also driving market growth, particularly in emerging economies. However, the market continues to face challenges from regulatory complexities, potential adverse effects of long-term hormone therapy, and fluctuations in raw material supply and production costs.

Key Market Drivers

Growth in Pharmaceutical Industry

The expanding focus on women's health, particularly related to menopause, fertility, and hormonal disorders, is a major factor driving demand for progesterone. As more women seek treatment for conditions like perimenopause, endometriosis, and PCOS, progesterone is increasingly used in HRT and therapeutic solutions. Rising age-related hormonal concerns in developed markets with greater healthcare access further support this trend.

In addition, the global burden of infertility is intensifying demand for ART procedures, in which progesterone is commonly administered to support embryo implantation and early pregnancy. With approximately 1 in 6 adults experiencing infertility globally, the need for effective, affordable, and accessible fertility care has grown. Progesterone's integral role in IVF and similar procedures is contributing to its rising use in fertility medications across both developed and developing markets, where awareness and accessibility of such treatments continue to expand.

Key Market Challenges

Safety Concerns and Side Effects

One of the major challenges in the progesterone market is the range of safety concerns and adverse effects associated with its long-term or high-dosage use, especially in HRT and fertility therapies. Common side effects include fatigue, bloating, mood changes, and headaches, while more severe risks such as thromboembolic events, cardiovascular complications, and increased cancer risk-particularly when used alongside estrogen-have raised caution.

In ART procedures, progesterone is essential for luteal phase support, but hormone supplementation may result in conditions like ovarian hyperstimulation syndrome (OHSS) and weight gain, which could deter treatment adherence. These health concerns affect prescription rates and patient trust, posing limitations to widespread adoption despite progesterone's clinical importance in reproductive care.

Key Market Trends

Rise in Menopause Awareness

Growing global awareness about menopause and related hormonal imbalances is shaping demand for effective hormone replacement therapies that include progesterone. With rising life expectancy and an expanding population of women aged 50 and above, the need for symptom management and quality-of-life improvements is increasing. Progesterone, when used with estrogen in HRT, mitigates risks such as endometrial cancer, making it a critical component of balanced therapy.

The trend toward bioidentical hormones, which closely replicate the body's natural hormone structure, is gaining traction. Bioidentical progesterone is increasingly preferred over synthetic alternatives due to its perceived safety and better compatibility with the body, making it a popular choice among women seeking natural options for menopause symptom management. This shift is fueling innovation and driving growth in the global progesterone market.

Key Market Players

• NAARI PHARMA Pvt. Ltd
• La Chandra Pharmalab
• BGP Laboratories Private Limited
• V M Lifescience
• Mankind Pharma Ltd
• Bhugan Lifescience Pvt Ltd
• Abcures Biosciences LLP
• Symbiotec Pharmalab
• Granth Pharma Pvt Ltd
• Emote Lifesciences LLP

Report Scope

In this report, the Global Progesterone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Progesterone Market, By Sales Channel:

• Direct
• Indirect

Progesterone Market, By End Use:

• Hormone Replacement Therapy
• Infertility Treatment
• Menstrual Disorders
• Premenstrual Syndrome (PMS)
• Others

Progesterone Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Progesterone Market.

Available Customizations

Global Progesterone Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Progesterone Market

5. Global Progesterone Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Hormone Replacement Therapy, Infertility Treatment, Menstrual Disorders, Premenstrual Syndrome (PMS), Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Progesterone Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Progesterone Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Progesterone Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Progesterone Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Progesterone Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Progesterone Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Progesterone Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Progesterone Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Progesterone Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Progesterone Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Progesterone Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Progesterone Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Progesterone Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Progesterone Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Progesterone Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Progesterone Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Progesterone Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Progesterone Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Progesterone Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Progesterone Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Progesterone Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Progesterone Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Progesterone Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Progesterone Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Progesterone Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. NAARI PHARMA Pvt. Ltd
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. La Chandra Pharmalab
• 15.3. BGP Laboratories Private Limited
• 15.4. V M Lifescience
• 15.5. Mankind Pharma Ltd
• 15.6. Bhugan Lifescience Pvt Ltd
• 15.7. Abcures Biosciences LLP
• 15.8. Symbiotec Pharmalab
• 15.9. Granth Pharma Pvt Ltd
• 15.10. Emote Lifesciences LLP

16. Strategic Recommendations

17. About Us & Disclaimer